The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects

被引:53
作者
Sun, Xiaoyan [1 ,2 ]
Wang, Weiguang [3 ]
Chen, Jiao [1 ,2 ]
Cai, Xueting [1 ,2 ]
Yang, Jie [1 ,2 ]
Yang, Yang [1 ,2 ]
Yan, Huaijiang [1 ,2 ]
Cheng, Xiaolan [1 ,2 ]
Ye, Juan [1 ,2 ]
Lu, Wuguang [1 ,2 ]
Hu, Chunping [1 ,2 ]
Sun, Handong [3 ]
Pu, Jianxin [3 ]
Cao, Peng [1 ,2 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Key Lab Drug Targets & Drug Leads Degenerat Dis, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Acad Tradit Chinese Med, Lab Cellular & Mol Biol, Nanjing, Jiangsu, Peoples R China
[3] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
B INDUCES APOPTOSIS; CANCER-CELLS; NEOPLASTIC-CELLS; SMALL-MOLECULE; EXPRESSION; SYSTEM; MECHANISMS; CARCINOMA; REDUCTASE; STRESS;
D O I
10.1158/0008-5472.CAN-16-0987
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrant expression of thioredoxin 1 (Trx1) plays an important role in cancer initiation and progression and has gained attention as an anticancer drug target. Here we report that the recently discovered natural diterpenoid isoforretin A (IsoA) significantly inhibits Trx1 activity and mediates anticancer effects in multiple preclinical settings. The inhibitory effect of IsoA was antagonized by free radical scavengers polyethylene glycol-catalase, polyethylene glycol superoxide dismutase, thiol- based antioxidants N-acetylcysteine and glutathione. Mass spectrometry analysis revealed that the mechanism of action was based on direct conjugation of IsoA to the Cys32/Cys35 residues of Trx1. This conjugation event attenuated reversible thiol reduction of Trx1, leading to ROS accumulation and a broader degradation of thiol redox homeostasis in cancer cells. Extending these in vitro findings, we documented that IsoA administration inhibited the growth of HepG2 tumors in a murine xenograft model of hepatocellular carcinoma. Taken together, our findings highlight IsoA as a potent bioactive inhibitor of Trx1 and a candidate anticancer natural product. (C)2016 AACR.
引用
收藏
页码:926 / 936
页数:11
相关论文
共 45 条
  • [1] [Anonymous], BMC CANC, DOI DOI 10.2174/138955711797247716
  • [2] The thioredoxin system in cancer
    Arner, Elias S. J.
    Holmgren, Arne
    [J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 420 - 426
  • [3] A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers
    Baker, A. F.
    Adab, K. N.
    Raghunand, N.
    Chow, H. H. S.
    Stratton, S. P.
    Squire, S. W.
    Boice, M.
    Pestano, L. A.
    Kirkpatrick, D. L.
    Dragovich, T.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 631 - 641
  • [4] Berggren M, 1996, ANTICANCER RES, V16, P3459
  • [5] Elucidation of thioredoxin as a molecular target for antitumor quinols
    Bradshaw, TD
    Matthews, CS
    Cookson, J
    Chew, EH
    Shah, M
    Bailey, K
    Monks, A
    Harris, E
    Westwell, AD
    Wells, G
    Laughton, CA
    Stevens, MFG
    [J]. CANCER RESEARCH, 2005, 65 (09) : 3911 - 3919
  • [6] Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells
    Farina, Antonietta R.
    Cappabianca, Lucia
    DeSantis, Giuseppina
    Di Ianni, Natalia
    Ruggeri, Pierdomenico
    Ragone, Marzia
    Merolle, Stefania
    Tonissen, Kathryn F.
    Gulino, Alberto
    Mackay, Andrew R.
    [J]. FEBS LETTERS, 2011, 585 (20) : 3328 - 3336
  • [7] Farina AR, 2001, EUR J BIOCHEM, V268, P405
  • [8] Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
    Grogan, TM
    Fenoglio-Prieser, C
    Zeheb, R
    Bellamy, W
    Frutiger, Y
    Vela, E
    Stemmerman, G
    Macdonald, J
    Richter, L
    Gallegos, A
    Powis, G
    [J]. HUMAN PATHOLOGY, 2000, 31 (04) : 475 - 481
  • [9] The thioredoxin system - From science to clinic
    Gromer, S
    Urig, S
    Becker, K
    [J]. MEDICINAL RESEARCH REVIEWS, 2004, 24 (01) : 40 - 89
  • [10] Kakolyris S, 2001, CLIN CANCER RES, V7, P3087